(Reuters) -Pfizer said on Friday that the U.S. Food and Drug Administration has approved its drug to treat adults with moderate-to-severe inflammatory bowel disease, ulcerative colitis.
The decision is based on the data from the late-stage study, in which the drug achieved all its primary and secondary goals.
The drug, Velsipity, was the key asset Pfizer picked up in its $6.7 billion deal for Arena Pharmaceuticals last year.
Ulcerative colitis affects around 1.25 million people in United States, according to the company.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Arun Koyyur)
